Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC. No dose-response relationship was detected as measured by PFS. These efficacy and safety results in mRCC support study in the phase III setting.

publication date

  • May 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4806782

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.59.0703

PubMed ID

  • 25452452

Additional Document Info

start page

  • 1430

end page

  • 7

volume

  • 33

number

  • 13